Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial

BACKGROUND: There are few effective therapies for coronavirus disease 2019 (COVID-19) upon the outbreak of the pandemic. To compare the effectiveness of a novel genetically engineered recombinant super-compound interferon (rSIFN-co) with traditional interferon-alpha added to baseline antiviral agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chuan, Luo, Fengming, Liu, Chengwu, Xiong, Nian, Xu, Zhihua, Zhang, Wei, Yang, Ming, Wang, Ye, Liu, Dan, Yu, Chao, Zeng, Jia, Zhang, Li, Li, Duo, Liu, Yanbin, Feng, Mei, Liu, Ruoyang, Mei, Jiandong, Deng, Senyi, Zeng, Zhen, He, Yuanhong, Liu, Haiyan, Shi, Zhengyu, Duan, Meng, Kang, Deying, Liao, Jiayu, Li, Weimin, Liu, Lunxu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906612/
https://www.ncbi.nlm.nih.gov/pubmed/33620016
http://dx.doi.org/10.1080/07853890.2021.1890329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906612/
https://www.ncbi.nlm.nih.gov/pubmed/33620016
http://dx.doi.org/10.1080/07853890.2021.1890329

Ejemplares similares